Featured Content

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.

Nano-pulse Stimulation Shows Early Preclinical Promise

NPS with electrodes is under investigation as a potential new ablative — and possibly immunotherapeutic — cancer treatment modality.

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations ...

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical ...

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

More Features>>>

Skin Cancer Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters